Cronos Group Inc (CRON)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.20B
Last updated: Nov 17, 2026 at 4:37 PM ET
Cronos Group Inc (CRON) Statistics
Cronos Group (CRON) has a market cap of $1.20B and an enterprise value of $787.17M. Revenue grew 47.86% over the last 12 months from the 12 months before. It holds $411.19M more cash than debt, 34.31% of its market cap.
Total Valuation
Enterprise value is 34.31% below the market cap, as cash exceeds debt.
| Market Cap | $1.20B |
|---|---|
| Enterprise Value | $787.17M |
| Latest price (Nov 17, 2026) | $3.19 |
Key Dates
| Last Earnings Date | Nov 5, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 5.5x and 1.1x. Its year-end P/E ranged from 12.7x to 191.8x from 2019 to 2025.
| P/E Ratio | 27.7x |
|---|---|
| Forward P/E | 19.8x |
| P/S Ratio | 5.5x |
| Forward P/S | 3.7x |
| P/B Ratio | 1.1x |
| P/TBV Ratio | 1.2x |
| P/FCF Ratio | 17.9x |
| P/OCF Ratio | 14.8x |
Enterprise Valuation
Counting debt and cash, the company is valued at 19.3x EBITDA and 11.6x free cash flow.
| EV / Earnings | 11.5x |
|---|---|
| EV / Sales | 3.7x |
| EV / EBITDA | 19.3x |
| EV / FCF | 11.6x |
Price Statistics
The stock is up 30.20% over 52 weeks and trades 3.92% below its 50-day average.
| Beta (1Y) | 0.38 |
|---|---|
| 52-Week Change | +30.20% |
| 1-Month Change | -1.85% |
| 3-Month Change | -3.04% |
| 6-Month Change | +22.22% |
| 5-Year Change | -36.42% |
| 10-Year Change | +267.98% |
| Total Return (1Y) | +30.20% |
| Total Return (3Y CAGR) | +17.62% |
| Total Return (5Y CAGR) | -8.19% |
| Return vs SPY (1Y) | +19.18% |
| Max Drawdown (1Y) | -26.91% |
| Max Drawdown (3Y) | -46.36% |
| Sharpe Ratio (1Y) | 0.68 |
| Correlation with SPY (1Y) | 0.13 |
| 50-Day Average | $3.32 |
| 200-Day Average | $2.90 |
| 52-Week Range | $2.28 to $3.91 |
| RSI (14 Days) | 40.1 |
| Average Volume (20 Days) | 1.17M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 12.71x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 12.71x |
|---|---|
| Quick Ratio | 11.91x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is 6.41% over the last 12 months, against a 5-year average of -9.55%.
| Return on Equity (ROE) | 6.41% |
|---|---|
| Return on Assets (ROA) | 5.74% |
| ROE (5Y Average) | -9.55% |
| ROA (5Y Average) | -9.14% |
| ROIC (5Y Average) | -3.39% |
| Asset Turnover | 0.18x |
| Inventory Turnover | 2.20x |
| Receivables Turnover | 5.11x |
| Cash Conversion Cycle | 186 days |
Scores
CRON has an Altman Z-Score of 11.19, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 11.19 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $214.16M over the last 12 months.
| Revenue | $214.16M |
|---|---|
| Revenue Growth (YoY) | +47.86% |
| Gross Profit | $96.08M |
| Operating Income | $7.10M |
| Pretax Income | $60.19M |
| Net Income | $68.71M |
| Reported EPS (TTM) | $0.12 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 89.17% of the $1.20B in total assets.
| Cash and Equivalents | $411.19M |
|---|---|
| Total Debt | $0 |
| Net Cash | $411.19M |
| Net Cash Per Share | $1.12 |
| Working Capital | $791.71M |
| Shareholder Equity | $1.07B |
| Book Value Per Share | $2.93 |
| Tangible Book Value | $1.00B |
| Tangible Book Per Share | $2.73 |
| Total Assets | $1.20B |
| Total Liabilities | $73.40M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $15.70M of capital spending, operating cash flow left $65.38M of free cash flow.
| Operating Cash Flow | $81.08M |
|---|---|
| Capital Expenditures | $15.70M |
| Free Cash Flow | $65.38M |
| FCF Per Share | $0.18 |
| Depreciation and Amortization | $15.47M |
| Share Repurchases | $46.54M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 3.32%.
| Gross Margin | 44.86% |
|---|---|
| Operating Margin | 3.32% |
| Pretax Margin | 28.11% |
| Net Margin | 32.08% |
| FCF Margin | 30.53% |
| Gross Margin (5Y Average) | 13.69% |
Growth
Revenue grew 19.11% a year over 3 years.
| Revenue Growth (3Y CAGR) | +19.11% |
|---|---|
| Revenue Growth (5Y CAGR) | +21.95% |
| Book Value Per Share Growth (2Y CAGR) | -0.80% |
| Tangible Book Per Share Growth (2Y CAGR) | -3.30% |
Dividends and Yields
CRON does not pay a dividend. Its free cash flow yield is 5.59%.
| Earnings Yield | 3.61% |
|---|---|
| FCF Yield | 5.59% |
| Buyback Yield | 3.98% |
Peer Position
Against 9 similar companies, CRON has the highest P/E.
P/E RatioPeer median 10.3x
P/S RatioPeer median 2.0x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +10.10%
| P/E Ratio | 27.7x vs 10.3x median |
|---|---|
| P/S Ratio | 5.5x vs 2.0x median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +47.86% vs +10.10% median |
Analyst Forecast
Consensus estimates put revenue growth at 65.07% and EPS growth at 216.60% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +65.07% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +216.60% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CRON
What is CRON's market cap?
Cronos Group has a market cap of $1.20B. Its enterprise value, which adds debt and subtracts cash, is $787.17M.
What is CRON's P/E ratio?
Cronos Group has a trailing P/E ratio of 27.7x and a forward P/E of 19.8x.
How many shares of CRON are outstanding?
Cronos Group has 366.47M shares outstanding. The count is down 4.29% from a year earlier.
Does CRON pay a dividend?
No. Cronos Group does not pay a dividend.
How much debt does CRON have?
Cronos Group has $0 of total debt and $411.19M of cash and equivalents, a net cash position of $411.19M.
CRON pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors